The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
-
Local Institution - 0330, Birmingham, Alabama, United States, 35209
Local Institution - 0329, Gilbert, Arizona, United States, 85234
Local Institution - 0015, La Jolla, California, United States, 92093
Local Institution - 0224, Los Alamitos, California, United States, 90720
Local Institution - 0370, Los Angeles, California, United States, 90017
Local Institution - 0364, Los Angeles, California, United States, 90048
Local Institution - 0016, San Francisco, California, United States, 94115
Local Institution - 0411, San Francisco, California, United States, 94121
Local Institution - 0238, Aurora, Colorado, United States, 80045
Local Institution - 0294, Denver, Colorado, United States, 80218
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
MALE
No
Celgene,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2029-01-19